Updates

In the article published by Susan Davis and colleagues in the [i]Journal of Clinical Endocrinology & Metabolism[/i] of December 2009, the authors compared the effects of two doses of the testosterone transdermal patch (TTP) with placebo on mammographic density in postmenopausal women without concomitant estrogen/progestin therapy (EPT) over a period of 52 weeks [1].  … Read More

A paper recently published by Kolios and colleagues addresses the effect of estrogen and alendronate on the healing of osteoporosis-related fractures in mice [1]. Three groups of ovariectomized mice and one control group received a soy-free diet. Two of the three groups of castrated mice additionally received either 17β-estradiol or alendronate in the diet. After… Read More

Patient Information Sheets from the Australasian Menopause Society now available on this website… Read More

[i]Note: the first part of this Commentary, The evidence, was issued on January 4, 2010.[/i] Author(s) Anne Gompel Unité de Gynécologie-Endocrinienne, APHP, Hôtel-Dieu Hospital and University Paris Descartes, France Citations Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587. doi: 10.1136/bmj.b2587. Published July 9, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19589821… Read More

A paper recently published by Esserman and colleagues addresses the question of screening for breast cancer and prostate cancer [1]. In this paper, the authors remind us that ‘Breast cancer and prostate cancer account for 26% of all cancers in the United States, with an estimated 386,560 patients diagnosed annually: 194,280 with breast cancer and… Read More

Reports on World Menopause Month 2009 - read more »… Read More

It has been proposed that a shift toward 2-hydroxyestrone (2-OHE1) from the 16α-hydroxyestrone (16-OHE1) metabolic pathway may be inversely associated with breast cancer risk because 2-OHE1 is thought to be less genotoxic and estrogenic than 16-OHE1. In the recently published study of Arslan and colleagues [1], serum levels and the ratio of the estradiol metabolites… Read More

In modern times, with the best medical care, most breast cancer patients survive the first years after diagnosis and look forward in anticipation that they are cured. Certainly, as time goes on without any signs of recurrence, the chance of winning this battle becomes higher. However, can we really talk about cure from breast cancer?… Read More

The metabolic syndrome is a complex of risk factors for cardiovascular disease and diabetes mellitus which are inter-related and cluster together more often than by chance. The five main risk factors include glucose abnormalities, dyslipidemia with low levels of high density lipoprotein (HDL) cholesterol or raised triglycerides, central obesity, and raised blood pressure. Insulin resistance… Read More

A recent paper by Crandall and colleagues, based on data from the Women’s Health Initiative (WHI) clinical trial, reported that ‘new-onset breast tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased breast cancer risk’ [1]. The authors assert that new-onset breast tenderness (NOBT) is a useful predictor of breast cancer and caution… Read More